PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF

The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Jong Min, JOO, Jeong Ho, SHIN, Hee Jong, KIM, Sung Hye, LEE, Jae Woong, CHO, Eui Hwan, KANG, Sung Hyun, CHO, Hyoung Min, HONG, Sung Pyo, AHN, Soon Kil, KI, Min Hyo, PARK, Yong Bin, KIM, Hyun Tae, KWON, Ho Seok, LEE, Keun Kuk
Format Patent
LanguageEnglish
Published 27.09.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid 10 cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation. 190
Bibliography:Application Number: SG20181106596T